Background. Famciclovir, the oral prodrug of penciclovir, is effective for the treatment of recurrent genital herpes. This randomized, clinic-initiated, double-blind trial compared the therapeutic efficacy and safety of treatment with famciclovir at dosages of 125 mg, 250 mg, and 500 mg twice daily for 5 days with placebo in immunocompetent adults with a recurrent episode of genital herpes.
Background. Famciclovir, the oral prodrug of penciclovir, is effective for the treatment of recurrent genital herpes. This randomized, clinic-initiated, double-blind trial compared the therapeutic efficacy and safety of treatment with famciclovir at dosages of 125 mg, 250 mg, and 500 mg twice daily for 5 days with placebo in immunocompetent adults with a recurrent episode of genital herpes.
Methods. Efficacy and tolerability were assessed in 308 patients with lesions present for no more than 6.5 h at the time of the first dose. Two assessments per day were performed to increase the precision of the determination of study end points.
Results. All doses of famciclovir were significantly more effective than placebo in reducing the time to cessation of viral shedding, complete lesion healing, and loss of all lesion-associated symptoms, particularly lesion tenderness, pain, and itching. Patients receiving treatment with famciclovir were significantly less likely to experience new lesions than were patients receiving placebo. All doses of famciclovir were tolerated as well as placebo was. There was no difference in efficacy or tolerability among the different doses of famciclovir; the lowest effective dose was 125 mg twice per day.
Conclusions. In immunocompetent adults with recurrent genital herpes, a 5-day course of famciclovir at a dosage of 125 mg, 250 mg, or 500 mg twice per day was significantly more effective than was placebo in reducing the duration of viral shedding and symptoms and in accelerating lesion healing. These results support the use of treatment with famciclovir at a dosage of 125 mg for 5 days as an effective, well-tolerated treatment for episodes of recurrent genital herpes.
Recurrent genital infection due to herpes simplex viruses (HSVs) is increasingly prevalent [1] . In patients with symptomatic disease due to HSV type 2 (HSV-2), there are an average of 4 recurrences per year [2] , leading to discomfort [3] and psychological morbidity [4] . For many patients, treatment of recurrences with antiviral therapy (i.e., episode treatment) is an effective way of managing recurrences. Aciclovir was the standard for episode treatment. Its poor oral bioavailability led to initial studies that included 5 doses per day [5] .
Treatment with valaciclovir, the prodrug of aciclovir, at a dosage of 500 mg twice daily was equivalent in efficacy and tolerability to treatment with aciclovir at a dosage of 200 mg 5 times per day [6, 7] , presumably because of improved oral absorption. Treatment with valaciclovir at a dosage of 1000 mg twice daily was no more effective than was treatment at a dosage of 500 mg received over 5 days [8] .
Famciclovir is the oral prodrug of penciclovir. Penciclovir has an antiviral spectrum and an oral bioavailability similar to those of aciclovir [8] . The bioavailability of penciclovir is markedly improved by use of its prodrug famciclovir [9] . When famciclovir is used, the bioavailability of penciclovir is 77% [9] , which compares favorably with the 55% bioavailability of aciclovir that occurs when valcyclovir is used [10] . This makes dosing twice per day appropriate from a pharmacokinetic point of view.
The efficacy and tolerability of oral famciclovir received twice daily for treatment of episodes of recurrent genital herpes have been demonstrated in a patient-initiated treatment trial [11] . Like valaciclovir [6, 7] , treatment with famciclovir received twice daily has also been shown to be as effective as aciclovir received 5 times per day for the treatment of recurrent episodes [12] . The current trial was initiated in the clinic and compared the efficacy and safety of 3 different dosages of famciclovir received twice daily for 5 days for the treatment of recurrent genital herpes with placebo.
METHODS

Trial Population
Healthy, presumably immunocompetent male and female patients aged 118 years with clinically diagnosed recurrent genital herpes who provided informed, written consent were included in the trial. Patients were required to have genital lesions that had not progressed beyond the ulcer stage at the time of enrollment nor had been present for 16.5 h at the time of the first study dose. The study was approved by the research ethics committees at all of the participating sites.
Exclusion criteria included the following: women who were not using an accepted method of birth control, were pregnant, were planning pregnancy, or were breast feeding; immunosuppression; use of antiviral therapy for HSV infection in the previous 4 weeks; presence of a lesion beyond the ulcer stage; and the presence of genital tract disorders that would interfere with the assessment of herpetic lesions.
Trial design
This was a clinic-initiated, double-blind, parallel-group study conducted at 5 centers in Canada (Health Sciences Centre, Winnipeg, Manitoba; Centre de Recherche en Infectiologie du CHUL, Quebec, Quebec; University of Alberta Hospital, Edmonton, Alberta; Viridae Clinical Sciences, Vancouver, British Columbia; and Centre Hospitalier de l'Université de Montréal, Montréal, Quebec) during the period October 1991-December 1992. At the screening visit, eligible patients were randomized to receive either famciclovir at a dosage of 125 mg, 250 mg, or 500 mg twice daily or placebo. When a patient had a recurrence of genital herpes, he or she presented to the clinic. A medical history was obtained, and symptoms and lesions were evaluated. Female patients with child-bearing potential underwent a urine pregnancy test, the results of which had to be negative for inclusion in the study. Blood and urine samples were obtained. Patients were offered an optional test for HIV antibody. Genital lesions were swabbed for HSV detection by cell culture. Patients received a blister pack marked with their patient number that contained 10 doses of medication for 5 days. The first dose of medication was taken after completion of the assessments (baseline, day 0), and subsequent doses were taken at 12-h intervals. If patients presented at the clinic before 10:00 p.m., they took 2 doses of trial medication on the first day. If they presented after 10:00 p.m., only 1 dose was taken on the first day, and the remaining dose was taken at the end of the 5-day period. The use of topical products on the genital lesions or oral corticosteroids was not permitted. Patients were, however, permitted to use mild oral analgesics.
Efficacy parameters and adverse events were assessed twice daily for the first 5 days of the trial and once daily thereafter until complete healing or patient withdrawal from the study. Patients were instructed to attend the clinic у6 h and !12 h after their previous visit. Therefore, patients attending late on day 0 may have attended the clinic only once on day 0.
Efficacy assessments. The time to cessation of viral shedding was defined as the time to the first viral culture with negative results after which no positive culture was obtained at subsequent visits. The time to complete healing was defined as the time to the first visit at which the patient reported no papules, vesicles, ulcers, or crusts, provided that the patient did not report any such symptom at a subsequent visit. For other variables, the time to cessation or loss was defined as the time to the first visit at which the variable was not reported (if the variable was not reported at subsequent visits). In all cases, time was measured from the start date and time of ingestion of trial medication.
Patients were excluded from the efficacy analysis if they missed у2 visits during the evaluation period until healing. Excluded patients included 3 from the 125-mg group, 0 from the 250-mg group, 5 from the 500-mg group, and 9 from the placebo group. The primary efficacy variables included the time to cessation of viral shedding from all genital lesions and the time to complete healing of original lesions. Secondary efficacy variables included the time to cessation of viral shedding from original lesions, the time to complete healing of all genital lesions, the time to cessation of each and all lesion-associated symptom(s), the time to cessation of lesion-associated edema, and the time to cessation of new lesion formation. All variables were also analyzed by sex.
At patient enrollment, original lesions were identified. New lesions were defined as those that developed after the start of treatment and were separated from other lesions by an area of uninvolved skin. Complete healing of lesions was defined as loss of crusts and reepithelialization, with only erythema remaining. Viral shedding was assessed by cell culture of lesion swab specimens.
At each assessment, investigators asked patients about lesion tenderness, pain, itching, burning, and tingling. Lesion-associated edema was also recorded.
Safety assessments. All adverse events identified by the investigator or elicited from the patient with the question, "Do you feel different in any way since starting the new treatment or since the last visit?" were recorded. The exceptions to this were symptoms and signs that formed part of the efficacy assessment. Serious adverse events were defined as any event that was fatal, life-threatening, permanently disabling, or incapacitating, resulted in hospitalization, prolonged a hospital stay, or was associated with congenital abnormality, malignancy, or overdose. At patient enrollment and again after completion of dosing, hematological and clinical chemistry parameters were measured, and urine samples were analyzed.
Statistical methods. The primary analysis was conducted on the intention-to-treat population, which comprised all patients who received at least 1 dose of trial medication. End point determinations were not utilized if the patient missed у2 consecutive visits immediately prior to the visit at which the end point was attained.
Efficacy data for each end point were evaluated with a timeto-event analysis, by means of a Cox proportional-hazards regression model. Only patients with the condition in question at some stage during the trial were included in the analysis. The generated hazard ratios compared the efficacy of treatment via pair-wise comparisons of placebo for each active group (125-mg group, 250-mg group, and 500-mg group). Median values for time to event, along with the first and third quartiles (interquartile range [IQR]), were also determined. Pair-wise comparison of famciclovir at dosages of 500 mg and 125 mg was conducted to determine the effect of dose on efficacy. For the analysis of all efficacy variables, the modified Bonferroni adjustment [13] was used to ensure that the overall error rate for the 4 comparisons did not exceed 5%. Differences with for 2-tailed tests were considered significant. P р .05
RESULTS
Patient Characteristics
A total of 308 patients were randomized to receive different trial treatments (table 1) . One woman was inadvertently entered into the trial twice, 31 days apart (receiving 250 mg and 125 mg of famciclovir on separate occasions). Her data were included in the analyses. There were no differences among groups with regard to the proportions of men and women or the median age of patients. A total of 245 patients (79%) opted to be tested for HIV infection; of these, 1 patient was HIV-1 infected. This patient was excluded from the efficacy-evaluable population. The protocol stated that patients would be excluded from the primary efficacy analysis if they missed у2 consecutive visits immediately prior to the visit at which the event occurred. The frequency at which exclusion for such reasons occurred was 4% (3 patients) in the 125-mg group, 0% (0 patients) in the 250-mg group, 4% (5 patients) in the 500-mg group, and 11% (9 patients) in the placebo group.
Genital lesions were culture-positive for HSV in 198 patients (64%) and culture-negative in 108 patients (35%). One pa- tient's sample was lost, and another patient had a culture that grew an unknown virus type. There were no significant differences among the treatment groups with respect to the proportion of HSV-infected patients. Samples obtained at various times throughout the course of the trial revealed that the majority of patients were infected with HSV-2 (72%). Of the remaining patients, 2% were infected with HSV type 1 (HSV-1), 2% had a culture that grew an unknown virus type, !1% was infected with HSV-1 and HSV-2, and no HSV was available for typing for 24%. At enrollment, 144 patients (47%) reported at least 1 papule, 157 (51%) reported at least 1 vesicle, and 79 (26%) reported at least 1 ulcer. No patient had a lesion that had progressed beyond the ulcer stage; 1 patient had no lesions. Most patients reported lesion-associated tenderness (82%) and itching (62%) (table 1) . Pain, burning, and tingling were also reported. In addition, there was lesion-associated edema in 52% of patients. There were no significant differences among groups with respect to the proportion of patients experiencing symptoms, with the exception of tingling, which was reported significantly more frequently in the 125-mg group. In general, symptoms were reported more frequently by women than by men. Between 53% and 62% of patients in each treatment group received concomitant medication, most frequently acetaminophen, ethinylestradiol, norethisterone, acetylsalicylic acid, and levonorgestrol.
There were 36 withdrawals, the distribution of which did not differ between the treatment groups (table 1). Only 1 patient was withdrawn from the study because of adverse events. This patient was receiving 250 mg of famciclovir twice daily and was withdrawn after 3 days of treatment because of nausea, headache, fatigue, and insomnia, all of which were considered to be probably related to trial medication. Twenty-four patients treated at one site were inadvertently withdrawn because of negative results of rapid overnight culture performed at enrollment. Other reasons for withdrawal included protocol violation (2 patients), perceived lack of efficacy (2 patients), loss to follow-up (3 patients), and miscellaneous reasons (4 patients). The median time to cessation of viral shedding from all genital lesions and from original lesions was slightly less in women (1.2-1.4 days for women receiving famciclovir and 3.2 days for women receiving placebo), compared with that in men (1.7-1.9 days for men receiving famciclovir and 3.7 days for men receiving placebo).
Time to complete healing of lesions. The time to complete healing of original lesions (the other primary efficacy variable) was significantly shorter for each of the 3 famciclovir groups, compared with the placebo group (figure 2). The median healing times for original lesions were consistently less for women receiving famciclovir (median days, 3.4-4.0 days) than for men receiving famciclovir (median days, 4.3-4.6). However, the hazard ratios were similar within each treatment group, indicating a similar effect of famciclovir on the rate of healing in men and women.
The time to complete healing of all genital lesions was significantly less for patients receiving famciclovir, compared with patients receiving placebo (table 2 Other efficacy variables. Significantly fewer patients receiving famciclovir at all 3 dose levels developed new lesions, compared with patients receiving placebo; altogether, 30% of patients receiving placebo developed new lesions. In comparison, one-half as many patients receiving famciclovir developed new lesions: 13% of the 125-mg group ( ), 14% of the P p .011 250-mg group ( ), and 14% of the 500-mg group P p .0207 ( ) . P p .0188
There was a significant reduction in the time to cessation of all lesion-associated symptoms in each famciclovir group, compared with the placebo group ( Effect of famciclovir dose on efficacy. Comparison of data from patients receiving 125 mg and 500 mg of famciclovir demonstrated no consistent additional benefit of receiving the higher dose instead of the lower dose, with respect to efficacy end points.
Tolerability
Similar proportions of patients in each treatment group reported adverse events, the most common of which were headache, nausea, fatigue, dizziness, and abdominal pain (table 4). The incidence of severe adverse events was low (4%-8%) and did not differ significantly among the treatment groups. There were no consistent changes in laboratory parameters at the end of the study. There were no serious adverse events recorded.
DISCUSSION
In this trial, famciclovir was significantly more effective than placebo for the treatment of a recurrent episode of genital herpes. This effect was observed for 3 dosages of famciclovir given at 12-h intervals for 5 days in immunocompetent patients with lesions not present 16.5 h at the time of the first dose. All dosages of famciclovir stopped viral shedding twice as fast as did placebo and effected lesion healing at least one-half of a day faster than did placebo. Patients receiving famciclovir were significantly less likely to form new lesions. Furthermore, treatment with famciclovir significantly reduced the duration of lesion-associated symptoms, including tenderness, itching, and pain, taken separately and together.
Pair-wise comparison revealed that the 500-mg dose offered no additional clinical benefits over the 125-mg dose (i.e., the dose-response curve was flat), which is currently recommended for treatment of episodes of recurrent genital herpes. Famciclovir was well tolerated at all dosages, as has been reported elsewhere [14, 15] .
These results parallel those of a similar trial, in which patients underwent therapy for a recurrent episode of genital herpes with the same 3 doses of famciclovir and placebo [11] . Treatment with famciclovir reduced the onset and duration of viral shedding, lesion persistence, and uncomfortable symptoms. In both this current trial and the earlier trial, twice-daily evaluations likely permitted more precise determinations of efficacy end points, compared with conventional once-daily assessments. This permitted construction of a more accurate profile of the time course of treatment effects on the disease.
The findings from this trial revealed some differences regarding sex in the response to treatment, as reported elsewhere [16] [17] [18] . Fewer male patients than female patients reported symptoms at enrollment, as reported elsewhere [19] , but it is unclear whether symptom-related differences in sex reflect differences in the experience of symptoms or differences in the desire to report symptoms. Hazard ratios indicated that the rate of loss of symptoms tended to be faster for male patients than for female patients. Median values indicated that the time to cessation of viral shedding and the time to lesion healing were generally slightly shorter among female patients than among male patients in the famciclovir groups and the placebo group.
The optimal drug regimen for treatment of episodes of recurrent genital herpes in healthy adults remains to be determined. Initial studies of aciclovir involved 200-mg doses received 5 times per day for 5 days [5] . Subsequent studies have demonstrated that regimens requiring 2 doses per day of famciclovir [12] and valaciclovir [6, 7] were as effective and well tolerated as aciclovir received 5 times per day. Most recently, the efficacy of a shorter, 2-day course of acyclovir [20] and a 3-day course of valaciclovir [21] have been demonstrated. Clearly, the optimal regimen has yet to be established.
Episode treatment is thus effective for managing recurrences for many patients and is perhaps preferable for patients ex-periencing infrequent recurrences. However, daily suppressive therapy has advantages. Dosages that include daily doses of acyclovir [22, 23] , famciclovir [24] , and valaciclovir [25] reduce the frequency of recurrences and symptomatic shedding. In addition, treatment with valaciclovir has been demonstrated to reduce transmission [25] .
In conclusion, this clinic-initiated trial demonstrated that treatment with famciclovir at a dosage as little as 125 mg twice daily was significantly more effective than placebo in accelerating lesion healing and reducing symptom duration and viral shedding in healthy adults with an episode of recurrent genital herpes. The significant effects were obtained by initiating therapy within 6.5 h of onset of a recurrence.
